翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300199 翰宇药业

已收盘 05-14 15:00:00

{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":14.38,"timestamp":1747206186000,"preClose":14.28,"halted":0,"volume":26480900,"delay":0,"changeRate":0.007,"floatShares":706000000,"shares":883000000,"eps":-0.1016,"marketStatus":"已收盘","change":0.1,"latestTime":"05-14 15:00:00","open":14.26,"high":14.5,"low":14.14,"amount":379000000,"amplitude":0.0252,"askPrice":14.39,"askSize":367,"bidPrice":14.38,"bidSize":1599,"shortable":0,"etf":0,"ttmEps":-0.1016,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747272600000},"marketStatusCode":5,"adr":0,"adjPreClose":14.28,"symbolType":"stock","openAndCloseTimeList":[[1747186200000,1747193400000],[1747198800000,1747206000000]],"highLimit":15.71,"lowLimit":12.85,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":19.45,"roa":"--","roe":"11.39%","epsLYR":-0.2,"committee":0.402584,"marketValue":12701000000,"turnoverRate":0.0375,"status":0,"floatMarketCap":10156000000},"requestUrl":"/m/hq/s/300199","defaultTab":"news","newsList":[{"id":"2534250262","title":"翰宇药业(300199.SZ)签署多肽创新药物联合开发协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2534250262","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534250262?lang=zh_cn&edition=full","pubTime":"2025-05-12 19:10","pubTimestamp":1747048254,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)公告，2025年5月9日，公司召开第六届董事会第四次会议，审议通过了《关于签署的议案》。同意公司与深圳碳云智肽药物科技有限公司(简称“碳云智肽”)就GLP-1R/GIPR/GCGR三重激动剂多肽创新药物签署联合开发协议。基于前期合作成果，为进一步推动项目进展，双方拟深化合作，计划联合开发多肽创新药物，多肽药物给药剂型包括但不限于注射剂、口服制剂等，应用于体重控制等代谢性疾病治疗领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1292131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0077","300199","06978","BK0188","BK0028","BK1161","BK0239","BK0070","159992"],"gpt_icon":0},{"id":"2534687242","title":"翰宇药业：与碳云智肽签署《GLP-1R/GIPR/GCGR三重激动剂多肽创新药物联合开发协议》","url":"https://stock-news.laohu8.com/highlight/detail?id=2534687242","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534687242?lang=zh_cn&edition=full","pubTime":"2025-05-12 18:22","pubTimestamp":1747045360,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159992","GLP","300199","BK1574","BK4160","GIPR","BK0070","BK1583","BK0188","BK0028","BK0077","BK1576","BK1141","BK4590","06978","03347","BK4144","BK1161","BK0239"],"gpt_icon":0},{"id":"2533631907","title":"翰宇药业(300199.SZ)：利拉鲁肽原料药获得韩国MFDS受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2533631907","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533631907?lang=zh_cn&edition=full","pubTime":"2025-05-06 21:28","pubTimestamp":1746538104,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，近日，公司全资子公司翰宇药业(武汉)有限公司的利拉鲁肽原料药获得韩国食品药品安全厅(以下简称“MFDS”)的审批受理。据悉，利拉鲁肽是人胰高血糖素样肽-1(Glucagon-like peptide-1，GLP-1)的类似物，GLP-1受体是重要的药物靶点，具有多种生理功能：血糖依赖性促进胰岛素分泌、保护胰岛β细胞、延迟胃排空以降低食欲等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0077","BK0188","BK0070","BK0239","300199"],"gpt_icon":0},{"id":"2533778055","title":"翰宇药业：利拉鲁肽原料药获韩国MFDS受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2533778055","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533778055?lang=zh_cn&edition=full","pubTime":"2025-05-06 17:09","pubTimestamp":1746522588,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["GLP","BK4144","300199","BK0070","BK0188","BK4590","BK0077","BK0239","BK0028"],"gpt_icon":0},{"id":"2531702376","title":"【翰宇药业：全资子公司翰宇武汉通过国家高新技术企业重新认定】翰宇药业公告，全资子公司翰宇武汉于近日收到《高新技术企业证书》，发证时间为2024年12月16日，有效期为三年。翰宇武汉此前已按15%的企业所得税税率进行纳税申报及预缴，本次通过高新技术企业的重新认定不会对公司经营业绩产生重大影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531702376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531702376?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:41","pubTimestamp":1746002467,"startTime":"0","endTime":"0","summary":"翰宇药业公告，全资子公司翰宇武汉于近日收到《高新技术企业证书》，发证时间为2024年12月16日，有效期为三年。翰宇武汉此前已按15%的企业所得税税率进行纳税申报及预缴，本次通过高新技术企业的重新认定不会对公司经营业绩产生重大影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30164150044125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0077","BK0070","BK0239","BK0028","300199","BK0188"],"gpt_icon":0},{"id":"2531920124","title":"翰宇药业4月29日现1笔大宗交易 成交金额220.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531920124","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531920124?lang=zh_cn&edition=full","pubTime":"2025-04-29 17:40","pubTimestamp":1745919600,"startTime":"0","endTime":"0","summary":"　　4月29日，翰宇药业收跌2.11%，收盘价为13.92元，发生1笔大宗交易，合计成交量15.86万股，成交金额220.77万元。　　第1笔成交价格为13.92元，成交15.86万股，成交金额220.77万元，溢价率为0.00%，买方营业部为机构专用，卖方营业部为中信证券股份有限公司泉州温陵北路证券营业部。　　进一步统计，近3个月内该股累计发生8笔大宗交易，合计成交金额为2237万元。该股近5个交易日累计下跌1.83%，主力资金合计净流出1.26亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-04-29/doc-ineuvnxv5693416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0239","BK0188","BK0070","300199","BK0077"],"gpt_icon":0},{"id":"2530720951","title":"翰宇药业（300199）2025年一季报简析：营收净利润同比双双增长，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2530720951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530720951?lang=zh_cn&edition=full","pubTime":"2025-04-27 06:37","pubTimestamp":1745707051,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期翰宇药业发布2025年一季报。截至本报告期末，公司营业总收入3.1亿元，同比上升106.29%，归母净利润6986.84万元，同比上升595.45%。本报告期翰宇药业短期债务压力上升，流动比率达0.31。本次财报公布的各项数据指标表现尚佳。融资分红：公司上市14年以来，累计融资总额25.15亿元，累计分红总额4.17亿元，分红融资比为0.17。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042700001910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2530440531","title":"翰宇药业(300199)3月31日股东户数5.73万户，较上期增加21.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530440531","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530440531?lang=zh_cn&edition=full","pubTime":"2025-04-26 17:14","pubTimestamp":1745658871,"startTime":"0","endTime":"0","summary":"证券之星消息，近日翰宇药业披露，截至2025年3月31日公司股东户数为5.73万户，较12月31日增加1.01万户，增幅为21.34%。在化学制药行业个股中，翰宇药业股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.15万户。从股价来看，2024年12月31日至2025年3月31日，翰宇药业区间涨幅为21.49%，在此期间股东户数增加1.01万户，增幅为21.34%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600011985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0077","BK0239","BK0070","300199"],"gpt_icon":0},{"id":"2530168802","title":"图解翰宇药业年报：第四季度单季净利润同比增58.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530168802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530168802?lang=zh_cn&edition=full","pubTime":"2025-04-26 01:14","pubTimestamp":1745601276,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业2024年年报显示，公司主营收入5.9亿元，同比上升36.82%；归母净利润-1.74亿元，同比上升66.21%；扣非净利润-2.4亿元，同比上升59.44%；其中2024年第四季度，公司单季度主营收入2.15亿元，同比上升620.69%；单季度归母净利润-1.39亿元，同比上升58.34%；单季度扣非净利润-1.46亿元，同比上升58.83%；负债率80.15%，投资收益154.59万元，财务费用1.14亿元，毛利率57.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042600000506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2530132108","title":"翰宇药业(300199.SZ)发布一季度业绩，扭亏为盈至6986.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530132108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530132108?lang=zh_cn&edition=full","pubTime":"2025-04-25 22:13","pubTimestamp":1745590407,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布2025年第一季度报告，该公司营业收入为3.1亿元，同比增长106.29%。归属于上市公司股东的净利润为6986.84万元。归属于上市公司股东的扣除非经常性损益的净利润为6555万元。基本每股收益为0.08元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300199","BK0188","BK0070","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2529064614","title":"多股涨停，CRO行业复苏回暖！凯莱英Q1净利润创阶段新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2529064614","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529064614?lang=zh_cn&edition=full","pubTime":"2025-04-24 13:12","pubTimestamp":1745471564,"startTime":"0","endTime":"0","summary":"多股业绩大增","market":"sg","thumbnail":"https://img3.gelonghui.com/cb090-c0a41afc-c0d5-4164-b2dd-e30dc1a84acc.jpg?guru_height=719&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/cb090-c0a41afc-c0d5-4164-b2dd-e30dc1a84acc.jpg?guru_height=719&guru_width=1280"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2089044","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06821","300199","002821","301509","688076"],"gpt_icon":0},{"id":"2529395377","title":"A股创新药板块震荡走高，华纳药厂涨超10%，热景生物涨超7%，东诚药业、百利天恒、翰宇药业跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529395377","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529395377?lang=zh_cn&edition=full","pubTime":"2025-04-22 10:40","pubTimestamp":1745289614,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["399300","BK1574","BK0077","688799","300199","06978","688506","159982","BK0188","688068","BK0028","BK1161","002675","BK0239","BK0070","159992"],"gpt_icon":0},{"id":"2529812479","title":"【A股创新药概念股走强，舒泰神、立方制药涨停】A股市场创新药概念股集体走强，其中，舒泰神20CM涨停，迪哲医药涨超13%，立方制药10CM涨停，康弘药业涨超8%，皓元医药、首药控股、苑东生物、艾迪药业、海南海药涨超6%，益方生物、信立泰涨超5%，君实生物、翰宇药业、博瑞医药、艾力斯涨超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529812479","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529812479?lang=zh_cn&edition=full","pubTime":"2025-04-21 10:56","pubTimestamp":1745204208,"startTime":"0","endTime":"0","summary":"A股市场创新药概念股集体走强，其中，舒泰神20CM涨停，迪哲医药涨超13%，立方制药10CM涨停，康弘药业涨超8%，皓元医药、首药控股、苑东生物、艾迪药业、海南海药涨超6%，益方生物、信立泰涨超5%，君实生物、翰宇药业、博瑞医药、艾力斯涨超4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/21105649700251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688197","688382","159992","000566","BK1515","300199","BK0216","BK0070","BK0077","BK1574","01877","BK0028","BK0146","BK0187","06978","BK1161","BK0196","BK0250","688192","688513","BK0197","399300","BK0183","003020","688131","BK1583","688488","688578","BK0046","BK0188","BK0239","688166","002294","002773","688180","BK0060","159982","BK0262","300204"],"gpt_icon":0},{"id":"2528633910","title":"翰宇药业：全资子公司替尔泊肽原料药获韩国MFDS受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2528633910","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528633910?lang=zh_cn&edition=full","pubTime":"2025-04-18 19:46","pubTimestamp":1744976778,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0077","BK4590","300199","BK0070","BK0028","BK0188","BK0239","BK4144","GLP"],"gpt_icon":0},{"id":"2528063303","title":"【翰宇药业：全资子公司替尔泊肽原料药获韩国MFDS受理】翰宇药业公告，全资子公司翰宇药业（武汉）有限公司的替尔泊肽原料药获得韩国食品药品安全厅（MFDS）的审批受理。替尔泊肽是一种新型GLP-1/GIP双受体激动剂，适用于2型糖尿病、肥胖症等治疗。该药品的受理将完善公司产品版图，提升公司竞争力，有望对公司业绩增长和行业地位产生积极影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528063303","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528063303?lang=zh_cn&edition=full","pubTime":"2025-04-18 19:44","pubTimestamp":1744976653,"startTime":"0","endTime":"0","summary":"翰宇药业公告，全资子公司翰宇药业（武汉）有限公司的替尔泊肽原料药获得韩国食品药品安全厅（MFDS）的审批受理。替尔泊肽是一种新型GLP-1/GIP双受体激动剂，适用于2型糖尿病、肥胖症等治疗。该药品的受理将完善公司产品版图，提升公司竞争力，有望对公司业绩增长和行业地位产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/18194449670548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["GLP","300199","BK0077","BK0070","BK0239","BK4590","BK0028","BK4144","BK0188"],"gpt_icon":0},{"id":"2528704856","title":"减肥药板块多数高开，金凯生科涨超10%，华东医药涨超4%，翰宇药业、百花医药等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528704856","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528704856?lang=zh_cn&edition=full","pubTime":"2025-04-18 09:27","pubTimestamp":1744939679,"startTime":"0","endTime":"0","summary":"减肥药板块多数高开，金凯生科涨超10%，华东医药涨超4%，翰宇药业、百花医药等跟涨。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/18092749644258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301509","BK0239","000963","LU1969619763.USD","LU2328871848.SGD","BK0183","BK0132","BK0175","BK0196","300199","BK0070","BK0216","BK0102","BK0187","BK0209","600721","BK0077","BK0028","BK0188"],"gpt_icon":0},{"id":"2528468701","title":"A股减肥药板块多数高开，金凯生科涨超10%，华东医药涨超4%，翰宇药业、百花医药等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528468701","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528468701?lang=zh_cn&edition=full","pubTime":"2025-04-18 09:27","pubTimestamp":1744939633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0028","301509","BK0175","600721","399300","BK0077","BK0187","LU1969619763.USD","BK0183","BK0196","BK0239","159982","BK0102","BK0209","BK0188","000963","BK0070","LU2328871848.SGD","BK0216","300199","BK0132"],"gpt_icon":0},{"id":"2528048847","title":"【减肥药概念盘初活跃 金凯生科涨超10%】减肥药概念盘初活跃，金凯生科涨超10%，昊帆生物、华东医药、翰宇药业、百花医药、一品红、常山药业等跟涨。消息面上，礼来口服减肥药Orforglipron三期临床数据亮眼，股价涨逾14%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528048847","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528048847?lang=zh_cn&edition=full","pubTime":"2025-04-18 09:26","pubTimestamp":1744939617,"startTime":"0","endTime":"0","summary":"减肥药概念盘初活跃，金凯生科涨超10%，昊帆生物、华东医药、翰宇药业、百花医药、一品红、常山药业等跟涨。消息面上，礼来口服减肥药Orforglipron三期临床数据亮眼，股价涨逾14%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"17136e9096e01d550821b3b9313a36c7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/18092649644252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1804176565.USD","IE0004445239.USD","300199","GB00BDT5M118.USD","LU2237438978.USD","SG9999014914.USD","SGXZ99366536.SGD","LU1983299246.USD","LU2237443895.HKD","LU0456855351.SGD","LU0256863902.USD","LU1551013425.SGD","000963","301509","LU1057294990.SGD","600721","SGXZ57979304.SGD","LU1069344957.HKD","301393","LU2357305700.SGD","LU2491050154.USD","LU2324357040.USD","IE00B2B36J28.USD","LU0385154629.USD","LU0708995401.HKD","LU0820561818.USD","LU1093756168.USD","LU0238689110.USD","LU2461242641.AUD","IE00BFTCPJ56.SGD","LU0097036916.USD","LU1720051108.HKD","LU2328871848.SGD","BK0070","LU2023250504.SGD","SG9999017495.SGD","LU2237443465.HKD","BK0028","300255","LU2361045086.USD","BK4599","300723","LU0122379950.USD","LU1868836914.USD","LU2112291526.USD","LU2265009873.SGD","IE00BJT1NW94.SGD","LU0256863811.USD","LU0203201768.USD"],"gpt_icon":0},{"id":"2527667044","title":"翰宇药业4月15日现1笔大宗交易 成交金额283.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527667044","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527667044?lang=zh_cn&edition=full","pubTime":"2025-04-15 17:00","pubTimestamp":1744707600,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　4月15日，翰宇药业收涨0.75%，收盘价为13.52元，发生1笔大宗交易，合计成交量21万股，成交金额283.92万元。　　第1笔成交价格为13.52元，成交21.00万股，成交金额283.92万元，溢价率为0.00%，买方营业部为机构专用，卖方营业部为中国国际金融股份有限公司深圳分公司。　　进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为2016.23万元。该股近5个交易日累计上涨4.00%，主力资金合计净流出1.7亿元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-04-15/doc-inetfxps7724011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0239","BK0188","300199","BK0070","BK0077"],"gpt_icon":0},{"id":"2527465552","title":"4月15日翰宇药业现1笔大宗交易 机构净买入283.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527465552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527465552?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:54","pubTimestamp":1744707284,"startTime":"0","endTime":"0","summary":"证券之星消息，4月15日翰宇药业发生大宗交易，交易数据如下：大宗交易成交价格13.52元，成交21万股，成交金额283.92万元，买方营业部为机构专用，卖方营业部为中国国际金融股份有限公司深圳分公司。近三个月该股共发生7笔大宗交易，合计成交1.34万手。该股近期无解禁股上市。截至2025年4月15日收盘，翰宇药业(300199)报收于13.52元，上涨0.75%，换手率5.6%，成交量39.57万手，成交额5.28亿元。该股最近90天内共有1家机构给出评级，买入评级1家。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041500025762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0239","BK0070","BK0077","BK0028","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1747211144153,"stockEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":0.0745},{"period":"3month","weight":0.1695},{"period":"6month","weight":0.1831},{"period":"1year","weight":0.1667},{"period":"ytd","weight":0.1078}],"compareEarnings":[{"period":"1week","weight":0.0177},{"period":"1month","weight":0.0422},{"period":"3month","weight":0.0085},{"period":"6month","weight":-0.0015},{"period":"1year","weight":0.0721},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"57273人(较上一季度增加21.34%)","perCapita":"12331股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":"　　深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业，主要产品包括多肽制剂药品、多肽原料药、客户定制肽、美容肽、固体制剂药品、医疗器械、多肽护肤品、大健康类产品等多个系列。公司上榜2023年广东制造业企业500强，并获得深圳市“专精特新”企业认定；翰宇武汉公司荣膺黄陂区“优秀先进制造业企业”，再次凸显公司高水准的质量优势。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}